CFCecilia Ferrari

Cecilia Ferrari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecilia Ferrari has a total of 275 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tumor Biology and Surgical Margin Patterns in Colorectal Liver Metastases: Association Between KRAS/BRAF Status and Type of Resection Margin—BRAF-KRAS LiverMet Collaborative Group

    by Cecilia Ferrari, Gian Mario D’AMbrosio, Victor Molina, Simone Famularo, Flavio Milana, Renato Patrone, Nadia Russolillo, Laura Alaimo, Ignacio Roldán-Ortiz, Nicola Nocchi, et al.

    Background: Surgical strategies for colorectal liver metastases (CRLM) have progressively evolved toward parenchyma-sparing approaches, increasing the relevance of understanding the relationship between tumor biology and resection margin patterns. In parallel, KRAS and BRAF mutations have emerged as key determinants of tumor behavior in CRLM. The interaction between mutational status and surgical margin type, however, remains insufficiently characterized. Methods: This multicenter retrospective study included patients undergoing curative-intent liver resection for CRLM between 2016 and 2021 across 17 international HPB centers. Clinicopathological variables were compared according to mutational status and margin type. Results: Among 1078 eligible patients, KRAS-mutated patients more frequently presented synchronous metastases, nodal involvement, and administration of perioperative chemotherapy compared with wild-type patients. Higher tumor burden was associated with both R1 parenchymal (R1P) and R1 vascular (R1V) resections. Within KRAS-mutated patients, synchronous disease and bilobar involvement were more frequently associated with R1P resections. Conclusions: KRAS/BRAF mutational status is associated with distinct clinicopathological patterns in patients undergoing liver resection for CRLM. Higher tumor burden and biologically aggressive disease features are more frequently associated with R1P and R1V resections, particularly among KRAS-mutated tumors.

  • ASO Visual Abstract: Prognostic Relevance of Surgical Margins According to KRAS and BRAF Status in Colorectal Liver Metastases—BRAF-KRAS LiverMet Collaborative Group

    by C. Ferrari, V. Molina, G. M. D’AMbrosio, S. Famularo, F. Milana, R. Patrone, N. Russolillo, L. Alaimo, I. Roldán-Ortiz, N. Nocchi, et al.

  • Prognostic Relevance of Surgical Margins According to KRAS and BRAF Status in Colorectal Liver Metastases: BRAF-KRAS LiverMet Collaborative Group

    by C. Ferrari, V. Molina, G. M. D’AMbrosio, S. Famularo, F. Milana, R. Patrone, N. Russolillo, L. Alaimo, I. Roldán-Ortiz, N. Nocchi, et al.


  • Open Access

    Comparative Analysis of Open, Laparoscopic, and Robotic Pancreaticoduodenectomy: A Systematic Review of Randomized Controlled Trials

    by Valentina Valle, Paraskevas Pakataridis, Tiziana Marchese, Cecilia Ferrari, Filippos Chelmis, Iliana N. Sorotou, Maria-Anna Gianniou, Aleksandra Dimova, Oleg Tcholakov, Benedetto Ielpo

    Background and Objectives: Various publications have compared outcomes among open (OPDs), laparoscopic (LPDs), and robotic pancreaticoduodenectomies (RPDs); however, the number of randomized controlled trials (RCTs) remains limited. This study aims to conduct a systematic review and analyze the outcomes between these approaches from randomized controlled trials. Materials and Methods: We performed a systematic literature search across PubMed/MedLine, Cochrane Library, ClinicalTrials.gov, and Google Scholar to identify relevant RCTs. The systematic review was conducted using the reporting items for systematic reviews and network meta-analyses guidelines (PRISMA-NMA) and registered in Prospero (CRD420251024475). For statistical analysis R software (version 4.3.2) was used. Results: Eight RCTs involving 1416 patients (706 OPDs, 600 LPDs, 110 RPDs) were included. LPD had a significantly longer operative time than OPD, while RPD showed no significant difference compared to OPD. Blood loss was reduced in both minimally invasive approaches. LPD showed a higher R0 resection rate and lower pancreatic fistula rate, whereas RPD had the lowest mortality. No significant differences were observed in major complications, reoperation, or readmission. LPD shortened hospital stay; RPD showed no difference. Conclusions: Although open pancreaticoduodenectomy remains a well-established standard, both laparoscopic and robotic approaches offer safe alternatives with distinct advantages. LPD is associated with shorter hospital stay and lower pancreatic fistula rates, whereas RPD demonstrates the lowest mortality. The lack of direct randomized comparisons between LPD and RPD highlights the need for further head-to-head trials.


  • Stratifying the risk in liver surgery: performance in an Italian cohort of 3.280 liver resection for HCC

    by Guido Costa, Matteo Donadon, Federica Cipriani, Matteo Serenari, Francesco Ardito, Andrea Fontana, Daniele Nicolini, Pasquale Perri, Maurizio Iaria, Mattia Garancini, et al.


  • Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries

    by Cecilia Ferrari, Piera Leon, Massimo Falconi, Ugo Boggi, Tullio Piardi, Laurent Sulpice, Davide Cavaliere, Edoardo Rosso, Mircea Chirica, Ferruccio Ravazzoni, et al.

    Background Due to delayed diagnosis and a lower surgical indication rate, left-sided pancreatic ductal adenocarcinoma (PDAC) is often associated with a poor prognosis in comparison to pancreatic head tumors. Multi-visceral resections (MVR) associated with distal pancreatectomy could be proposed for patients presenting with locally infiltrating disease. Methods We retrospectively analyzed a multi-centric cohort of left-sided PDAC patients operated on from 2009 to 2020. Thirteen European high-volume HPB centers participated in this study. We analyzed patients who underwent distal pancreatectomy (DP) associated with MVR and compared them to standard DP patients. Results Among 258 patients treated curatively for PDAC of the body and tail, 28 patients successfully underwent MVR. A longer operative time was observed in the MVR group (295 min +/− 74 vs. 250 min +/− 96, p= 0.248). The post-operative complication rate was comparable between the two groups (46.4% in the MVR group vs. 62.2% in the control group, p= 0.108). The incidence of positive margin (R1) was similar between the two groups (28.6% vs. 26.6%; p=0.827). After a median follow-up of 25 (9–111) months, overall survival was comparable between the two groups (p= 0.519). Conclusions Multi-visceral resection in left-sided pancreatic ductal adenocarcinoma is safe and feasible and should be considered in selected cases as it seems to provide acceptable surgical and oncological outcomes.


  • Survival benefit of second line therapies for recurrent hepatocellular carcinoma: repeated hepatectomy, thermoablation and second-line transplant referral in a real life national scenario

    by Simone Famularo, Umberto Cillo, Andrea Lauterio, Matteo Donadon, Alessandro Vitale, Matteo Serenari, Federica Cipriani, Federico Fazio, Mario Giuffrida, Francesco Ardito, et al.


  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival

    by Cecilia Ferrari, Letizia Cuniolo, Matteo Mascherini, Matteo Santoliquido, Stefano DI Domenico, Franco DE Cian

    Background/Aim: Rectal cancer (RC) represents 30% of colon cancers. Despite the progress achieved in integrated chemoradiotherapy and surgical multidisciplinary treatments, the rate of local recurrence (LR) is 3.7-13%. Multivisceral resections allow many patients with pelvic recurrence to be treated in a curative manner. The purpose of this work is to assess the impact of surgery for rectal cancer patients with pelvic recurrence. Patients and Methods: In a retrospective study from 2013 to 2018, data was collected from patients who had undergone rectal resection for adenocarcinoma. We compared perioperative data, postoperative outcomes, oncological results, and survival rates. Results: 106 rectal cancer patients (40-87 years old) requiring surgery were included. The local recurrence rate was 15% (15 patients). LR patients requiring intervention were nine (56%) who underwent sphincter sparing surgeries, and 6 (44%) who underwent surgeries with sphincter resection. There was no statistically significant difference (p=0.416) in the 5-year overall survival rate of patients without recurrence compared to those with pelvic recurrence. Conclusion: Curative surgery for local recurrence from rectal cancer is safe and feasible and should be considered in selected cases as it seems to provide acceptable surgical and oncological outcomes.

  • Biliary Tree Cysts and Surgical Treatment: Outcomes in a Multicentric Study

    by Cecilia Ferrari, Manuel Blanco Rodríguez, Víctor Molina, Belén Martín, Marina Espinet, Andrea Percivale, Guido Griseri, Antonio Moral, Santiago Sánchez-Cabús

    Background: Biliary tree cysts (BTCs) represent an either localized or multifocal abnormal dilatation of the biliary tree, which entails an increased risk of acute cholangitis and cholangiocarcinoma (2.5%–16%). Its incidence in Western countries is ∼1/100.000–1/150.000, being more frequent in Asia (1/1.000). These cysts are usually classified according to Todani classification, which is based on site and morphology of cysts. Patients and Methods: This is a retrospective multicentric descriptive study of patients surgically treated for BTCs. From 2005 to 2018, 25 cases were collected between Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) and Ospedale San Paolo (Savona, Italy). Clinical presentation was characterized by abdominal pain, jaundice, fever, and sometimes weight loss. Eight patients presented Todani type I, 1 patient Todani type II, 3 patients Todani III, 1 patient Todani type IV, and 12 patients Todani type V. Results: Among the 25 surgically treated patients, 12 patients underwent liver resection, 7 patients underwent resection of the extrahepatic biliary tree, 3 patients underwent BTC removal through a duodenotomy, 1 patient underwent resection of the extrahepatic biliary tree and liver resection, and 2 patients underwent pancreatoduodenectomy. Overall 30-day morbidity rate was 20%, and 90-day mortality was 0%. Pathologic examination confirmed diagnosis of cholangiocarcinoma in 5 patients (20%). After a median follow-up of 59 months, 20 patients are alive and in good conditions, whereas 50% of patients with cholangiocarcinoma died for disease progression. Conclusions: Surgical treatment for BTCs is associated with acceptable postoperative outcomes, with moderate morbidity and null mortality rates. Moreover, the risk of developing cholangiocarcinoma is still high that prompts surgical treatment once diagnosis is made.


  • The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group

    by Maurizio Iaria, Giorgio Bianchi, Federico Fazio, Francesco Ardito, Pasquale Perri, Nicholas Pontarolo, Simone Conci, Matteo Donadon, Matteo Zanello, Quirino Lai, et al.